Interferon-alpha versus somatostatin or the combination of both in metastatic neuroendocrine gut and pancreatic tumours.
Neuroendocrine tumours of the gastroenteropancreatic system represent a therapeutic challenge. Current therapeutic strategies will be presented and discussed with especial consideration given to biotherapeutic regimens in metastatic tumour disease.
Faiss
S
S
Department of Internal Medicine and Gastroenterology, Universitätsklinikum Benjamin Franklin, Freie Universität Berlin, Germany.
Scherübl
H
H
Riecken
E O
EO
Wiedenmann
B
B
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D015282:Octreotide / Q000627:therapeutic use*; D010190:Pancreatic Neoplasms / Q000188:drug therapy*; D010456:Peptides, Cyclic / Q000627:therapeutic use*; D011994:Recombinant Proteins; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013274:Stomach Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal; D007370:Interferon Type I; D010456:Peptides, Cyclic; D011994:Recombinant Proteins; C060347:lanreotide; D013004:Somatostatin; D015282:Octreotide